An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast

Author： Gottlieb A. B.   Strober B.   Krueger J. G.   Rohane P.   Zeldis J. B.   Hu C. C.   Kipnis C.  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.24, Iss.5, 2008-05, pp. : 1529-1538

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Canakinumab for the Treatment of Children With Colchicine‐Resistant Familial Mediterranean Fever: A 6‐Month Open‐Label, Single‐Arm Pilot Study

By  

ARTHRITIS & RHEUMATOLOGY, Vol. 66, Iss. 11, 2014-11 ,pp. : 3241-3243

John Wiley & Sons Inc

Access to resources Recommend Favorite

Paricalcitol Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients: A German-Austrian, Single-Arm, Open-Label, Prospective, Noninterventional, Observational Study

By  

Nephron Clin Pract, Vol. 126, Iss. 1, 2014-01 ,pp. : 39-50

Karger

Access to resources Recommend Favorite

Efficacy and safety of open‐label ixekizumab treatment in Japanese patients with moderate‐to‐severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis

By  

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY, Vol. 29, Iss. 6, 2015-06 ,pp. : 1148-1155

John Wiley & Sons Inc

Access to resources Recommend Favorite

GOAL: multicenter, open-label, post-marketing study of flavocoxid, a novel dual pathway inhibitor anti-inflammatory agent of botanical origin

By Pillai Lakshmi   Burnett Bruce P.   Levy Robert M.    

Current Medical Research and Opinion, Vol. 26, Iss. 5, 2010-05 ,pp. : 1055-1063

Informa Healthcare

Access to resources Recommend Favorite

An open‐label, single‐arm, phase 2 trial of the polo‐like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer

By  

CANCER, Vol. 120, Iss. 7, 2014-04 ,pp. : 976-982

John Wiley & Sons Inc

Access to resources Recommend Favorite